Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

摘要: Purpose Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study cediranib in patients with recurrent glioblastoma. Methods Cediranib, oral pan-VEGF receptor tyrosine kinase inhibitor, was administered (45 mg/d) until progression or unacceptable toxicity to The primary end point the proportion alive and free at 6 months (APF6). magnetic resonance imaging (MRI) plasma urinary biomarker evaluations multiple time points. Results Thirty-one glioblastoma were accrued. APF6 after 25.8%. Radiographic partial responses observed MRI 17 (56.7%) 30 evaluable using three-dimensional measurements eight (27%) two-dimensional measurements. For 15 who entered taking corticosteroids, dose reduced (n = 10...